急性髓系白血病DNA异常甲基化及治疗进展
收稿日期: 2020-01-03
网络出版日期: 2022-07-25
基金资助
甘肃省科技计划项目(20JR5RA595)
冯秀娟, 吴涛, 白海 . 急性髓系白血病DNA异常甲基化及治疗进展[J]. 内科理论与实践, 2021 , 16(04) : 282 -286 . DOI: 10.16138/j.1673-6087.2021.04.013
| [1] | 马娟, 沈立松. DNA甲基化基因DNMT3A在急性髓系白血病M_4和M_5发病机制的研究进展[J]. 诊断学理论与实践, 2017, 16(4):446-448 |
| [2] | 刘莉, 李绵洋. CTNNA1基因启动子区异常甲基化与急性髓系白血病的相关性分析[J]. 检验医学与临床, 2016, 13(7): 907-908. |
| [3] | 陈婉淑, 张梦露, 韩冰. 骨髓增生异常综合征和急性髓系白血病的基因突变比较[J]. 中华血液学杂志, 2021, 42(2): 171-176. |
| [4] | Potter N, Miraki-Moud F, Ermini L, et al. Single cell analysis of clonal architecture in acute myeloid leukaemia[J]. Leukemia, 2019, 33(5): 1113-1123. |
| [5] | Hamidi T, Singh AK, Chen T. Genetic alterations of DNA methylation machinery in human diseases[J]. Epigenomics, 2015, 7(2): 247-265. |
| [6] | 王攀, 赵洪林, 任凡, 等. 表观遗传学在恶性肿瘤发生发展和治疗中的新进展[J]. 中国肺癌杂志, 2020, 23(2): 91-100. |
| [7] | 常乃柏. DNA甲基化靶向药物在急性髓系白血病中的应用[J]. 中国肿瘤临床, 2017, 44(2): 64-67. |
| [8] | 邓春阳, 陈双, 江明, 等. 多基因甲基化在骨髓增生异常综合征患者中的预后价值[J]. 中国实验血液学杂志, 2017, 25(4): 1118-1122. |
| [9] | 周念, 胡建达. 成人急性髓系白血病新的基因突变与预后相关性研究进展[J]. 临床血液学杂志, 2014, 27(1): 75-79. |
| [10] | Jones PA, Baylin SB. The epigenomics of cancer[J]. Cell, 2007, 128(4): 683-692. |
| [11] | 罗丽卿, 彭振翼, 司秀文, 等. 急性髓细胞白血病IDH基因突变临床特征及预后意义[J]. 中华肿瘤防治杂志, 2017, 24(21): 1530-1533. |
| [12] | Da Costa EM, McInnes G, Beaudry A, et al. DNA methylation-targeted drugs[J]. Cancer J, 2017, 23(5): 270-276. |
| [13] | 高展, 刘延方, 王冲, 等. DNMT3A R882位点突变急性髓系白血病临床分析[J]. 郑州大学学报(医学版), 2017, 52(3): 300-303. |
| [14] | 张前鹏, 韩永胜, 皖湘, 等. 地西他滨与传统化疗治疗中、高危骨髓增生异常综合征的临床比较[J]. 中国实验血液学杂志, 2018, 26(1): 197-201. |
| [15] | Li H, Wang L, Wu Y, et al. Very-low-dose decitabine is effective in treating intermediate- or high-risk myelodysplastic syndrome[J]. Acta Haematol, 2017, 138(3): 168-174. |
| [16] | 王明. DNA甲基化检测及其在急性髓系白血病和骨髓增生异常综合征中的临床应用分析[J]. 中国现代医生, 2018, 56(12): 1-4. |
| [17] | 陆敏秋, 鲍立, 禇彬, 等. 地西他滨单药治疗中高危骨髓增生异常综合征和急性髓系白血病的疗效观察[J]. 中国全科医学, 2020, 23(35): 4443-4447. |
| [18] | Bocchia M, Candoni A, Borlenghi E, et al. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy[J]. Hematol Oncol, 2019, 37(4): 447-455. |
| [19] | 康思静, 王婷婷, 高然, 等. 地西他滨联合小剂量CAG治疗老年急性髓系白血病疗效研究[J]. 中国实用内科杂志, 2016, 36(5): 406-407. |
| [20] | Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia[J]. J Clin Oncol, 2012, 30(21): 2670-2677. |
| [21] | Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine[J]. Proc Natl Acad Sci USA, 2010, 107(16): 7473-7479. |
| [22] | Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia[J]. Leukemia, 2013, 27(9): 1803-1812. |
| [23] | Santini V, Ossenkoppele GJ. Hypomethylating agents in the treatment of acute myeloid leukemia: a guide to op-timal use[J]. Crit Rev Oncol Hematol, 2019, 8: 1401-1407. |
| [24] | Yun S, Vincelette ND, Abraham I, et al. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials[J]. Clin Epigenetics, 2016, 8(3): 68-77. |
| [25] | Sockel K, Wermke M, Radke J, et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse[J]. Haematologica, 2011, 96(10): 1568-1570. |
| [26] | Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia[J]. J Clin Oncol, 2010, 28(4): 562-569. |
| [27] | Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B[J]. J Clin Oncol, 2002, 20(10): 2429-2440. |
| [28] | Pleyer L, Döhner H, Dombret H, et al. Azacitidine for front-line therapy of patients with AML[J]. Int J Mol Sci, 2017, 18(2): 415. |
| [29] | de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study[J]. Cancer, 2010, 116(23): 5420-5431. |
| [30] | 刘炜洋, 王小钦. 阿扎胞苷治疗骨髓增生异常综合征和急性髓系白血病的研究进展[J]. 上海医药, 2019, 40(11): 8-12. |
| [31] | Lübbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy[J]. J Clin Oncol, 2011, 29(15): 1987-1996. |
| [32] | Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes[J]. N Engl J Med, 2016, 375(21): 2023-2036. |
| [33] | 孙妍珺, 徐杨, 吴德沛, 等. 地西他滨联合预激方案治疗53例复发难治正常核型急性髓系白血病的疗效分析[J]. 中华血液学杂志, 2015, 36(12): 1025-1030. |
| [34] | 石晓东, 戴钰俊, 杨莹, 等. 西罗莫司靶向治疗DNA甲基转移酶3A突变的急性髓系白血病的研究[J]. 内科理论与实践, 2018, 13(3): 175-180. |
| [35] | Dai YJ, Wang YY, Huang JY, et al. Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement[J]. Proc Natl Acad Sci USA, 2017, 114(20): 5237-5242. |
/
| 〈 |
|
〉 |
